MA55909A - Inhibiteurs de cdk - Google Patents
Inhibiteurs de cdkInfo
- Publication number
- MA55909A MA55909A MA055909A MA55909A MA55909A MA 55909 A MA55909 A MA 55909A MA 055909 A MA055909 A MA 055909A MA 55909 A MA55909 A MA 55909A MA 55909 A MA55909 A MA 55909A
- Authority
- MA
- Morocco
- Prior art keywords
- cdk inhibitors
- cdk
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019085494 | 2019-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55909A true MA55909A (fr) | 2022-03-16 |
Family
ID=73051265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055909A MA55909A (fr) | 2019-05-05 | 2020-05-05 | Inhibiteurs de cdk |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20220296595A1 (fr) |
| EP (2) | EP3966213A4 (fr) |
| JP (2) | JP2022531687A (fr) |
| KR (1) | KR20220004755A (fr) |
| CN (2) | CN114364675A (fr) |
| AU (2) | AU2020269469A1 (fr) |
| BR (1) | BR112021022105A2 (fr) |
| CA (1) | CA3138973A1 (fr) |
| CL (1) | CL2021002903A1 (fr) |
| CO (1) | CO2021016504A2 (fr) |
| EA (1) | EA202193015A1 (fr) |
| IL (1) | IL287767A (fr) |
| MA (1) | MA55909A (fr) |
| MX (1) | MX2021013531A (fr) |
| SG (1) | SG11202112229UA (fr) |
| TW (2) | TW202108572A (fr) |
| WO (2) | WO2020224568A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112020500A (zh) | 2017-12-22 | 2020-12-01 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的氨基吡啶衍生物 |
| AU2020215684A1 (en) * | 2019-01-29 | 2021-08-12 | Beta Pharma, Inc. | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
| SG11202112229UA (en) * | 2019-05-05 | 2021-12-30 | Qilu Regor Therapeutics Inc | Cdk inhibitors |
| CA3197985A1 (fr) * | 2020-11-20 | 2022-05-27 | Qingsong Liu | Derives de dihydroisoquinolinone et d'isoindolinone et leurs utilisations |
| WO2023143482A1 (fr) * | 2022-01-29 | 2023-08-03 | 上海辉启生物医药科技有限公司 | Composé ou sel de 2-aminopyrimidine, son procédé de préparation et son utilisation |
| US20230322792A1 (en) * | 2022-04-08 | 2023-10-12 | Biolexis Therapeutics, Inc. | Cdk9 inhibitors |
| CN117645604A (zh) * | 2022-09-05 | 2024-03-05 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| UY27487A1 (es) * | 2001-10-17 | 2003-05-30 | Boehringer Ingelheim Pharma | Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación |
| WO2008003766A2 (fr) * | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | Nouveaux composés |
| PA8852901A1 (es) * | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| SG10202004716RA (en) * | 2014-07-24 | 2020-06-29 | Beta Pharma Inc | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| CN105732615B (zh) * | 2014-12-31 | 2018-05-01 | 山东轩竹医药科技有限公司 | Cdk激酶抑制剂 |
| US9969719B2 (en) * | 2015-03-11 | 2018-05-15 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug |
| TWI736578B (zh) * | 2016-02-06 | 2021-08-21 | 大陸商上海複尚慧創醫藥研究有限公司 | 6-5元稠合唑環衍生物及其藥物組合物，以及作為藥物的應用 |
| CN107286134B (zh) * | 2016-04-11 | 2019-04-12 | 上海勋和医药科技有限公司 | 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用 |
| MX2018012622A (es) * | 2016-04-15 | 2019-08-29 | Epizyme Inc | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. |
| WO2018045957A1 (fr) * | 2016-09-07 | 2018-03-15 | 江苏豪森药业集团有限公司 | Inhibiteur de cdk4/6, son procédé de préparation et son application |
| TWI732083B (zh) * | 2016-12-22 | 2021-07-01 | 大陸商貝達藥業股份有限公司 | 苯并咪唑衍生物、其藥物組合物及其應用 |
| WO2018121766A1 (fr) * | 2016-12-30 | 2018-07-05 | 上海医药集团股份有限公司 | Composé hétérocyclique fusionné contenant de l'azote, procédé de préparation, intermédiaire, composition et utilisation associés |
| CN108794452B (zh) * | 2017-05-05 | 2021-05-28 | 上海时莱生物技术有限公司 | 具有激酶抑制活性的化合物、其制备方法和用途 |
| CN109503573A (zh) * | 2017-09-14 | 2019-03-22 | 昆明圣加南生物科技有限公司 | 2-取代苯胺基嘧啶衍生物及其用途 |
| US10519136B2 (en) * | 2017-12-29 | 2019-12-31 | Accutar Biotechnology | Dual inhibitors of PARP1 and CDK |
| BR112020015405A2 (pt) * | 2018-01-29 | 2020-12-08 | Beta Pharma, Inc. | Compostos de 2h-indazóis como inibidores cdk4 e cdk6, composições farmacêuticas que os compreendem, seus usos terapêuticos e métodos de preparação |
| SG11202112229UA (en) * | 2019-05-05 | 2021-12-30 | Qilu Regor Therapeutics Inc | Cdk inhibitors |
-
2020
- 2020-05-05 SG SG11202112229UA patent/SG11202112229UA/en unknown
- 2020-05-05 JP JP2021565881A patent/JP2022531687A/ja active Pending
- 2020-05-05 TW TW109114894A patent/TW202108572A/zh unknown
- 2020-05-05 MA MA055909A patent/MA55909A/fr unknown
- 2020-05-05 AU AU2020269469A patent/AU2020269469A1/en active Pending
- 2020-05-05 CA CA3138973A patent/CA3138973A1/fr active Pending
- 2020-05-05 EP EP20802696.3A patent/EP3966213A4/fr active Pending
- 2020-05-05 US US17/608,915 patent/US20220296595A1/en active Pending
- 2020-05-05 CN CN202080049033.9A patent/CN114364675A/zh active Pending
- 2020-05-05 BR BR112021022105A patent/BR112021022105A2/pt unknown
- 2020-05-05 MX MX2021013531A patent/MX2021013531A/es unknown
- 2020-05-05 KR KR1020217039756A patent/KR20220004755A/ko unknown
- 2020-05-05 EA EA202193015A patent/EA202193015A1/ru unknown
- 2020-05-05 WO PCT/CN2020/088585 patent/WO2020224568A1/fr active Application Filing
-
2021
- 2021-05-04 AU AU2021268648A patent/AU2021268648A1/en active Pending
- 2021-05-04 EP EP21727336.6A patent/EP4146647A1/fr active Pending
- 2021-05-04 CN CN202180046122.2A patent/CN115803327B/zh active Active
- 2021-05-04 WO PCT/US2021/030728 patent/WO2021226140A1/fr unknown
- 2021-05-04 US US17/922,804 patent/US20230174512A1/en active Pending
- 2021-05-04 JP JP2022567388A patent/JP2023525005A/ja active Pending
- 2021-05-05 TW TW110116234A patent/TW202144351A/zh unknown
- 2021-11-01 IL IL287767A patent/IL287767A/en unknown
- 2021-11-04 CL CL2021002903A patent/CL2021002903A1/es unknown
- 2021-12-03 CO CONC2021/0016504A patent/CO2021016504A2/es unknown
-
2023
- 2023-09-26 US US18/373,060 patent/US20240066031A1/en active Pending
- 2023-09-26 US US18/373,067 patent/US20240033264A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220004755A (ko) | 2022-01-11 |
| US20220296595A1 (en) | 2022-09-22 |
| EA202193015A1 (ru) | 2022-03-17 |
| WO2021226140A1 (fr) | 2021-11-11 |
| IL287767A (en) | 2022-01-01 |
| CN115803327A (zh) | 2023-03-14 |
| CL2021002903A1 (es) | 2022-07-08 |
| JP2022531687A (ja) | 2022-07-08 |
| JP2023525005A (ja) | 2023-06-14 |
| EP4146647A1 (fr) | 2023-03-15 |
| CA3138973A1 (fr) | 2020-11-12 |
| MX2021013531A (es) | 2022-02-11 |
| BR112021022105A2 (pt) | 2021-12-28 |
| EP3966213A4 (fr) | 2023-04-19 |
| CO2021016504A2 (es) | 2022-01-17 |
| SG11202112229UA (en) | 2021-12-30 |
| US20240033264A1 (en) | 2024-02-01 |
| CN114364675A (zh) | 2022-04-15 |
| US20230174512A1 (en) | 2023-06-08 |
| US20240066031A1 (en) | 2024-02-29 |
| TW202108572A (zh) | 2021-03-01 |
| AU2021268648A1 (en) | 2023-01-19 |
| EP3966213A1 (fr) | 2022-03-16 |
| WO2020224568A1 (fr) | 2020-11-12 |
| TW202144351A (zh) | 2021-12-01 |
| CN115803327B (zh) | 2024-02-13 |
| AU2020269469A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54543A (fr) | Inhibiteurs de kif18a | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| MA55909A (fr) | Inhibiteurs de cdk | |
| MA53287A (fr) | Inhibiteurs de prmt5 | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| DK3774817T3 (da) | Bcl6-hæmmere | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| MA55477A (fr) | Inhibiteurs de hpk1 | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| DK3738452T3 (da) | Fordamper | |
| DK3710457T3 (da) | Immunproteasomhæmmere | |
| KR20220035377A (ko) | 람노오스-다당류 | |
| DK3720840T3 (da) | Cathepsinhæmmere | |
| AR128365A1 (es) | Inhibidores de parp7 | |
| ES1243687Y (es) | Salmorejo | |
| IT201900020430A1 (it) | Espositore | |
| DE202019004111U8 (de) | Weichenstellvorichtung | |
| TH190914S (th) | ขันโตก | |
| TH190910S (th) | ขันโตก | |
| TH190911S (th) | ขันโตก |